Pharmaceutical formulation development involves various components in addition to the active pharmaceutical ingredients. In recent years, excipient development is become core area of research in pharmaceutical drug delivery because it influences the formulation development and drug delivery process in various ways. Biopolymers are choice of research as excipient because of its low toxicity, bio...

pharmaceutical inventions are considered as the most challengers of intellectual property issue. the principal reasons of these are essential function of pharmaceutical in human life and health in addition to its high economic value. there are several challenges between developing and developed countries in the field of pharmaceutical patent; however, a new challenge has been caused so-called “...

gabapentin is an anticonvulsant widely used in the treatment of epilepsy. no peculiar chromophore is available on the gabapentin moiety for direct analysis by absorption spectrophotometry. a sensitive spectrophotometric method for the determination of gabapentin in bulk, pharmaceutical formulations and human plasma has been developed. in this method, gabapentin directly derivatized with vanilli...

Central Research Laboratories, Wakunaga Pharmaceutical Co., Ltd., a Shimokotachi 1624 Kohda-cho, Takata-gun, Hiroshima 729-64, Japan, Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine, b Kasumi, Minami-ku, Hiroshima 734, Japan, National Institute of Hygienic Sciences, Tsukuba Medicinal Plant Research Station, c Hachimandai, Yatabe-cho, Tsukuba, Ibaraki 305, Japan, To...

This paper examines a change in business practices in the pharmaceutical manufacturer-to-distributor supply chain, a change that essentially forced pharmaceutical distributors to maintain lower inventories. This change also provided pharmaceutical manufacturers with information about distributor customer demand and inventories that had previously been withheld from them. Supply chain theory and...

#no abstract#

Today, the goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption — that is, widespread or systemic practices, usually legal, that undermine an institution’s objectives or integrity. In this symposium, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and wh...